Royal Philips has received 510(k) clearance from the US Food and Drug Administration (FDA) for its computed tomography (CT) imaging solutions for low-dose lung cancer screening (LCS).
The approval was granted for the suite of CT solutions, including 27 CT and PET/CT models, as well as software and services.
Philips’ low-dose CT solutions will help healthcare organizations ranging from community hospitals to multi-facility health systems to build full-bodied lung cancer screening programs.
The lung cancer screening solutions will provide various benefits for patients and referring physicians, including personalized management of radiation dose, better insights throughout the process and advanced image data sharing and analytics.
Philips diagnostic imaging CEO Rob Cascella said: "Our robust portfolio of CT solutions offers our customers in the United States a turnkey approach to lung cancer screening.
"This is a complementary offering to utilize existing systems to bring low-dose CT screening to healthcare facilities of all sizes who want to drive earlier detection for patients at high risk for lung cancer."
Through its integrated radiology solutions and services, the firm will work with healthcare executives to better evaluate availability of existing scanners and establish an enterprise-wide lung cancer program that will deliver advanced patient care and access.
Image: A chest X-ray showing a tumor in the lung. Photo: courtesy of James Heilman, MD.